Enveda Reports Phase I Data
Enveda has reported the first data from phase I of ENV-308, a tablet that mimics Lac-Phe, a compound whose levels increase after exercise. By the time of release on August 18, 88 healthy adults had been enrolled in the study. The next phase is expected to test whether the candidate can help maintain weight loss after discontinuing GLP-1 receptor agonists and appetite suppressants.
The path to ENV-308 began with Lac-Phe, a compound whose levels increase after physical exercise. In a 2022 study published in Nature, researchers observed this increase in mice, horses, and humans. In obese mice, pharmacological elevation of Lac-Phe reduced food intake, fat mass, and body weight. In animals with impaired Lac-Phe synthesis, exercise was less effective at preventing weight gain. These results linked one of the signals of physical exercise to the regulation of food behavior.
Enveda reports that Lac-Phe is rapidly cleared from the body, so the company is developing ENV-308 as a daily tablet that should replicate its action. According to Enveda, the company found the candidate using PRISM, an artificial intelligence model trained on 1.2 billion mass spectra of small molecules. In phase I, the safety, tolerability, and pharmacokinetics of the drug are tested. According to Enveda, the study found no serious adverse events, discontinuations, or dose interruptions. The company also measured leptin, a hormone that informs the brain about energy stores, and reported a decrease in its blood levels. Phase II is planned for people who have stopped or plan to stop GLP-1 therapy, and Enveda intends to test whether ENV-308 can maintain weight loss and other metabolic parameters.
🔗 Read original →
PubMed Central (PMC)
An exercise-inducible metabolite that suppresses feeding and obesity
Exercise confers robust protection against obesity, type 2 diabetes, and other cardiometabolic diseases.1–5 However, the molecular and cellular mechanisms that mediate the metabolic benefits of physical activity remain unclear.6 Here we show that ...
August 25, 2026 6
